Q-omics provides the consensus-scored SHISAL2B profile across patient tissues and cancer cell-line models. SHISAL2B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SHISAL2B is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, SHISAL2B RNA expression shows 11,345 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, LUSC, and TGCT as cancer lineages where SHISAL2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHISAL2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHISAL2B survival associations across molecular data types. SHISAL2B RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHISAL2B RNA expression–survival associations across cancer types. High SHISAL2B expression shows unfavorable associations in KICH, BRCA, THYM and OV, but favorable associations in LGG and ESCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KICH as the clearest survival context for SHISAL2B RNA expression.
This table summarizes SHISAL2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SHISAL2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHISAL2B shows lower tumor expression in PRAD and STAD and higher tumor expression in LUSC, COAD, LUAD and KIRC. The LUSC box plot shows higher SHISAL2B RNA expression in tumor versus normal tissue (log2 FC = +0.236, t-test p = .001).
This table shows molecular features associated with SHISAL2B in patient tissues and cancer cell lines. In patient samples, SHISAL2B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SHISAL2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_SCLC.
